The current analysis demonstrates the long-term benefits of deutetrabenazine for patients with TD who remain on treatment for up to 3 years, representing the longest prospective assessment in TD for a VMAT2 inhibitor. This evidence concerns the gene SLC18A2 and thanatophoric dysplasia.